Skip to main content
. 2017 Mar 21;8(22):35946–35961. doi: 10.18632/oncotarget.16412

Figure 7. Reparixin potentiates anti-neoplastic effects of chemoterapics on TC cells.

Figure 7

Cell viability of 8505c, CAL62 and SW1736 cells left untreated (NT), or treated with Reparixin (10 μM), Docetaxel (DOCE-50 pM) or Doxorubicin (DOXO-5 nM) alone (white bars) or in combination (black bars) at 72 h. The percent (%) of live cells was reported. *p < 0.05 compared to the relative control.